Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
New 52-week readouts from Lilly’s TOGETHER-PsO and TOGETHER-PsA trials add one-year data on the concomitant use of its ixekizumab and tirzepatide treatments in patients with psoriatic conditions and excess weight.
THE APEX TIMES
THE APEX TIMES
A new market analysis suggests investors should watch whether Amylyx can translate early GLP-1 progress into credible commercial differentiation at a time when Eli Lilly remains the dominant U.S. GLP-1 franchise.
THE APEX TIMES
The FDA has approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, giving Eli Lilly a broader label to pursue beyond glucose control.
THE APEX TIMES
A recent market note says UnitedHealth Group has outperformed healthcare-plan stocks over the past year, keeping Wall Street’s outlook on the company relatively constructive.
THE APEX TIMES
The approvals extend Moderna’s push beyond a single product cycle, indicating how the company plans to pair next-generation COVID formulations with an mRNA influenza entry.
THE APEX TIMES
CVS Health shares have retreated more than 12% over the past month, but some market commentary suggests the company’s valuation may not be as damaged as the stock move implies.
THE APEX TIMES
A new market analysis says Eli Lilly’s dominance in GLP-1 medicine is a starting point, not a finish line, and that three issues will shape how the outlook gets measured from here.
THE APEX TIMES
A recent market commentary argues that Novo Nordisk is searching for a new “catalyst” to reassert its lead in weight-loss GLP-1 medicines, with convenience emerging as a potential differentiator as investors weigh how it could affect Eli Lilly’s outlook.
THE APEX TIMES
The stock of Johnson & Johnson (JNJ) has led the consumer staples sector in recent performance, while analysts remain only moderately upbeat about the company’s near-to-medium term outlook, market coverage said on Aug. 29, 2026.
